Added to YB: 2024-12-11
Pitch date: 2024-12-11
TMDX [bullish]
TransMedics Group, Inc.
+82.12%
current return
Author Info
MMMT Wealth is a CPA who shares stock pitches in their newsletter. Sign up for the newsletter.
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$4.5B
Pitch Price
$67.62
Price Target
N/A
Dividend
N/A
EV/EBITDA
35.52
P/E
51.63
EV/Sales
7.99
Sector
Health Care Equipment and Supplies
Category
growth
TransMedics (TMDX): Revolutionizing Transplantation with Multi-Organ Perfusion Technology
TMDX: Only multi-organ portable perfusion tech. 10k+ transplant goal. Untapped donor pool (20% lungs, 30% hearts, 60% livers). Reduced PGD 50-65%, ischemic biliary complications 84%. Command Center moat. 2025 growth: next-gen lung/heart, NOP network. Kidney launch 2029 (+50k TAM). Next-gen OCS for 30k+ transplants/year. International expansion planned.
Read full article (2 min)